Navigation Links
Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies
Date:11/9/2009

PHILADELPHIA November 9, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced the availability of INTUNIV (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17. INTUNIV, a once-daily formulation of guanfacine, is the first and only nonscheduled alpha-2A receptor agonist approved for the treatment of ADHD. In clinical trials, INTUNIV provided significant efficacy across the spectrum of ADHD symptoms that can be disruptive, such as being easily distracted, interrupting others, running around excessively, arguing with adults, and losing temper.

"INTUNIV has been shown to improve a range of ADHD symptoms and provides prescribers and patients with another treatment option for this complex disorder," said Rakesh Jain, MD, MPH, Director of Psychopharmacology Research at R/D Clinical Research, Inc, in Lake Jackson, Texas. "In clinical studies, INTUNIV was shown to provide significant ADHD symptom improvement across a full day, as reported by parents at approximately 6 PM, 8 PM, and 6 AM the next morning. These findings suggest that INTUNIV may be an important treatment option for children and adolescents with ADHD who are faced with the complexities of the disorder, both at school and at home. Because of this, many clinicians such as myself, have been highly anticipating its availability."

The US Food and Drug Administration (FDA) approved INTUNIV on September 2, 2009. Once-daily INTUNIV is now available in US pharmacies in four dosage strengths (1 mg, 2 mg, 3 mg, and 4 mg) and is marketed in the United States by the existing Shire ADHD sales team of nearly 600 representatives. INTUNIV is not a controlled substance and has no known potential for abuse or dependence.

"INTUNIV is the newest ADHD treatment to receive FDA approval and the latest addit
'/>"/>

Contact: Matt Cabrey
mcabrey@shire.com
484-595-8248
Porter Novelli
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine
2. FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
3. Photo: Levemir(R) Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in TITRATE(R) Study
4. New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
5. Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States
6. Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
7. Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
8. Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
9. European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1
10. Once-Daily Combo Works for New HIV Patients
11. Labopharms Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
(Date:12/25/2014)... December 26, 2014 The report ... to 2023” focuses on the current treatment landscape, ... the colorectal cancer market. Stivarga is a drug ... or rectal cancer. Boehringer Ingelheim is developing nintedanib ... treatment of refractory CRC in the US, Europe, ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... be one of the hottest styles in the next few ... company releases 26 A-line sweetheart evening dresses, and announces the ... “We are trying our best to help a lady to ... with affordable prices, we provide discounted delivery costs to our ...
(Date:12/25/2014)... CA (PRWEB) December 25, 2014 The short ... was created in honor of a true 9/11 hero, ... two film festivals including the 24 hours of Nuremberg International ... in Bangladesh. , Actress, screenwriter and director Luciana ... produce this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... Woodland Hills, California (PRWEB) December 25, 2014 ... in her home in Woodland Hills, California after an ... Harris passed away on Christmas Eve evening in her ... battle with aggressive metastatic breast cancer. ... International for over forty years, she pioneered and championed ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... Prescribed TherapiesSACRAMENTO, Calif., May 11 The California chapter ... network of over 250 physicians with the shared mission ... treatments and therapies, today cited a recent survey of ... number of physicians believe insurance companies are getting in ...
... May 11 Cell Therapeutics, Inc. ("CTI" or the "Company") ... of Directors has authorized a "Modified Dutch Auction" tender offer ... of its common stock, no par value ("Common Stock"), and ... principal amount for the following outstanding shares of the Company,s ...
... . , Montreal, May 11, 2009 When ... an equal hand. The latest study by Dr. Maya Saleh, ... and McGill University, shows that women have a more powerful ... by females could have a beneficial effect on the innate ...
... The National Organization for Rare Disorders (NORD) will honor ... cutting-edge television network, and several pioneering companies developing treatments ... the National Press Club in Washington, DC, on Thursday, ... which researchers and others are honored for significant achievements ...
... Aon Corporation (NYSE: AOC ) Chairman, Lester B. ... 15, 2009 at 10:00 a.m. Central Time. A webcast of ... Chicago will be available via the Internet. This listen-only webcast ... web site at www.aon.com . The webcast ...
... 50 percent by the 14th test, study finds, , , MONDAY, ... you undergo, the higher your risk of having at least ... may seem like common sense, it,s not something that patients ... in the May/June issue of the Annals of Family ...
Cached Medicine News:Health News:Alliance for Patient Access Wants Health Care Code of Conduct 2Health News:Cell Therapeutics, Inc. Intends to Offer to Exchange up to $89.2 Million of its Outstanding Convertible Notes in a 'Modified Dutch Auction' Tender Offer 2Health News:Cell Therapeutics, Inc. Intends to Offer to Exchange up to $89.2 Million of its Outstanding Convertible Notes in a 'Modified Dutch Auction' Tender Offer 3Health News:Equality of the sexes? Not always when it comes to biology 2Health News:NORD to Honor Rare Disease Pioneers 2Health News:NORD to Honor Rare Disease Pioneers 3Health News:Aon to Webcast Annual Shareholders' Meeting 2Health News:More Cancer Tests Mean More False-Positive Results 2Health News:More Cancer Tests Mean More False-Positive Results 3
(Date:12/24/2014)... FLINT, Mich. , Dec. 24, 2014  Diplomat ... largest independent specialty pharmacy, is proud to announce ... and quality at Diplomat, will take office as the ... 2015. The formal induction ceremony will take place Feb. ... which will be held at the Renaissance Center in ...
(Date:12/24/2014)... SCHOFIELD, Wis. , Dec. 23, 2014 ... and marketer of over-the-counter (OTC) medicinal and healthcare products, ... production of MigraPure® H, a hemp-based, advanced headache relief ... marijuana dispensaries in Colorado , ... . With the MigraPure H Advanced ...
(Date:12/24/2014)... SAN DIEGO , Dec. 23, 2014 ResMed ... a significant patent infringement action against Chinese medical device manufacturer ... Commission (ITC) ruled today that BMC,s masks listed below infringe ... advertising, or selling these masks in the United ... , iVolve N2 nasal mask , Willow nasal pillows ...
Breaking Medicine Technology:Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... , JOHANNESBURG, South Africa, Nov. 26 The 2009 ... Award in the Generic Pharmaceutical Market is presented to ... ) , For the Company of the Year Award, ... performance against key competitors: growth strategy and implementation, degree ...
... , WESTON, Fla., Nov. 25 American Scientific ... that they have opened a regional marketing and production management office ... location abroad, providing an essential gateway for the development and production ... adults to be distributed and sold globally. Currently the company ...
Cached Medicine Technology:Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4American Scientific Resources Inc. Opens Shanghai Location 2
... Lyphochek Elevated Immunosuppressant Control is a ... whole blood. This unique product is ideal ... very high Cyclosporine levels, such as C2 ... patients at two hours post-dose., ,Lyphochek Elevated ...
Liquichek Hematology-16T Control is a hematology reference control used in monitoring determinations of blood cell values on TOA SYSMEX cell counters....
NEW Liquichek Reticulocyte Control (A)is an assayed whole blood control for evaluating the precision of automated methods of reticulocyte counting....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Medicine Products: